AKYA Stock Overview A life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Akoya Biosciences, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Akoya Biosciences Historical stock prices Current Share Price US$3.00 52 Week High US$6.31 52 Week Low US$1.88 Beta 1.18 1 Month Change 26.05% 3 Month Change 6.57% 1 Year Change -40.94% 3 Year Change -73.36% 5 Year Change n/a Change since IPO -88.48%
Recent News & Updates Quanterix Corporation (NasdaqGM:QTRX) entered into an agreement to acquire Akoya Biosciences, Inc. (NasdaqGS:AKYA) from Telegraph Hill Partners III, L.P, a fund managed by Telegraph Hill Partners, PSC Capital Partners LLC, aMoon Growth Fund II, L.P., a fund managed by aMoon Fund and others for $190 million. Jan 11
Market Cool On Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Pushing Shares 29% Lower Dec 14
Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA) Nov 19 Akoya Biosciences, Inc. Revises Earnings Guidance for the Full Year 2024 Nov 15
Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt? Nov 12
Precision for Medicine to Offer Spatial Biology Solutions Incorporating the PhenoCycler-Fusion 2.0 System and the new Phenocode Discovery IO60 Panel from Akoya Biosciences Nov 07 See more updates Quanterix Corporation (NasdaqGM:QTRX) entered into an agreement to acquire Akoya Biosciences, Inc. (NasdaqGS:AKYA) from Telegraph Hill Partners III, L.P, a fund managed by Telegraph Hill Partners, PSC Capital Partners LLC, aMoon Growth Fund II, L.P., a fund managed by aMoon Fund and others for $190 million. Jan 11
Market Cool On Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Pushing Shares 29% Lower Dec 14
Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA) Nov 19 Akoya Biosciences, Inc. Revises Earnings Guidance for the Full Year 2024 Nov 15
Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt? Nov 12
Precision for Medicine to Offer Spatial Biology Solutions Incorporating the PhenoCycler-Fusion 2.0 System and the new Phenocode Discovery IO60 Panel from Akoya Biosciences Nov 07
Akoya Biosciences, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Oct 28
Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company Oct 08
Akoya Biosciences, Inc. Announces Board Changes Oct 04
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target Aug 09
Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint Aug 06
Akoya Biosciences, Inc. Updates Earnings Guidance for the Full Year of 2024 Aug 06
New major risk - Share price stability Aug 04
Akoya Biosciences, Inc. to Report Q2, 2024 Results on Aug 05, 2024 Jul 16
Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost Jun 27
Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment? Jun 24
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now May 29
Consensus EPS estimates fall by 31% May 21
Akoya Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024 May 15
Price target decreased by 11% to US$8.17 May 14
Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA) May 10
Akoya Biosciences and Shanghai KR Pharmtech Announces Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows May 03
Akoya Biosciences, Inc., Annual General Meeting, Jun 04, 2024 Apr 24
Akoya Biosciences, Inc. to Report Q1, 2024 Results on May 13, 2024 Apr 23
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions At AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale Apr 05
Consensus EPS estimates upgraded to US$0.83 loss Mar 12
Full year 2023 earnings: EPS exceeds analyst expectations Mar 05
Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load? Feb 28
Akoya Biosciences, Inc. to Report Q4, 2023 Results on Mar 04, 2024 Feb 09
High number of new directors Feb 01
Akoya Biosciences Deploys the Maxfuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory At Stanford University for Multiomic Integration of Spatial and Single-Cell Data on the Enable Medicine Platform Jan 09
Akoya Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 and for the Fiscal Year 2024 Jan 08
Price target decreased by 11% to US$9.25 Dec 19
Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump Nov 25
Consensus EPS estimates upgraded to US$1.46 loss Nov 16
New minor risk - Share price stability Nov 15
Price target decreased by 8.3% to US$11.00 Nov 12
Akoya Biosciences, Inc. Reiterates Revenue Guidance for the Fiscal Year 2023 Nov 10
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 10
Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023 Nov 01
Price target decreased by 7.1% to US$13.13 Oct 17
Akoya Biosciences, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Oct 12
Akoya Biosciences, Inc. Launches PhenoCycler-Fusion 2.0 and Phenoimager HT 2.0 Platform Upgrades Sep 20
Chief Operating Officer recently bought US$92k worth of stock Sep 12
Akoya Biosciences, Inc. Provides Revenue Guidance for the Fiscal Year 2023 Aug 09
Price target decreased by 12% to US$14.14 Aug 08
Akoya Biosciences, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Jul 13
Price target decreased by 8.6% to US$16.00 Jul 10
New minor risk - Share price stability Jun 14 Akoya Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $43.5 million. Jun 10
Akoya Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $43.5 million. Jun 09
Akoya Biosciences, Inc. Announces Executive Changes Jun 08
First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat May 10
Akoya Biosciences, Inc. Provides Revenue Guidance for the Full Year 2023 May 09
Price target decreased by 7.9% to US$17.50 Apr 21
Consensus EPS estimates fall by 11%, revenue upgraded Mar 15
Full year 2022 earnings: EPS misses analyst expectations Mar 08
Akoya Biosciences, Inc. to Report Q4, 2022 Results on Mar 06, 2023 Feb 07
Akoya Biosciences, Inc. to Present First-of-its-Kind Spatial Multiomics Dataset at 2023 AGBT General Meeting Feb 02
Akoya Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Fiscal Year 2022 Jan 09
Chief Financial Officer exercised options to buy US$2.2m worth of stock. Dec 28
Chief Financial Officer exercised options and sold US$298k worth of stock Dec 18
President exercised options and sold US$59k worth of stock Dec 09
Co-Founder recently sold US$67k worth of stock Dec 03
Co-Founder notifies of intention to sell stock Nov 18
Co-Founder recently sold US$325k worth of stock Nov 16
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 09 Akoya Biosciences, Inc Launches PhenoCode Signature Panels to Accelerate Development of Predictive Biomarkers for Cancer Immunotherapy
Akoya Biosciences, Inc. to Report Q3, 2022 Results on Nov 07, 2022 Oct 12
Co-Founder recently sold US$319k worth of stock Sep 14
President exercised options and sold US$63k worth of stock Sep 10
Price target increased to US$20.40 Aug 22
Consensus forecasts updated Aug 16
Akoya Biosciences, Inc. Raises Earnings Guidance for the Full Year 2022 Aug 09
Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 09
Akoya Biosciences, Inc. to Report Q2, 2022 Results on Aug 08, 2022 Jul 13
Price target decreased to US$18.60 Jun 22
President notifies of intention to sell stock Jun 19
Akoya Biosciences Seeks Growth Despite Higher Operating Losses May 30
Consensus forecasts updated May 13
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? May 11
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 06
Akoya Biosciences, Inc. Revises Revenue Guidance for the Full Year of 2022 May 06
Price target decreased to US$20.50 Apr 27
Akoya Biosciences, Inc., Annual General Meeting, Jun 01, 2022 Apr 22
Akoya Biosciences Announces Ehab A. El-Gabry, MD, as Chief Medical Officer Apr 20
Chief Business Officer exercised options to buy US$844k worth of stock. Apr 15
Akoya Biosciences, Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 15
Consensus forecasts updated Mar 22
Full year 2021 earnings: EPS misses analyst expectations Mar 15 Shareholder Returns AKYA US Life Sciences US Market 7D -6.5% 0.5% -0.2% 1Y -40.9% -1.0% 23.7%
See full shareholder returns
Return vs Market: AKYA underperformed the US Market which returned 23.7% over the past year.
Price Volatility Is AKYA's price volatile compared to industry and market? AKYA volatility AKYA Average Weekly Movement 13.3% Life Sciences Industry Average Movement 9.7% Market Average Movement 6.5% 10% most volatile stocks in US Market 18.8% 10% least volatile stocks in US Market 3.3%
Stable Share Price: AKYA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AKYA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services.
Show more Akoya Biosciences, Inc. Fundamentals Summary How do Akoya Biosciences's earnings and revenue compare to its market cap? AKYA fundamental statistics Market cap US$146.74m Earnings (TTM ) -US$57.97m Revenue (TTM ) US$86.82m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) AKYA income statement (TTM ) Revenue US$86.82m Cost of Revenue US$36.71m Gross Profit US$50.11m Other Expenses US$108.08m Earnings -US$57.97m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.17 Gross Margin 57.72% Net Profit Margin -66.77% Debt/Equity Ratio 556.8%
How did AKYA perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/29 00:07 End of Day Share Price 2025/01/29 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Akoya Biosciences, Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Mark Massaro BTIG Kyle Mikson Canaccord Genuity Timothy Chiang Capital One Securities, Inc.
Show 7 more analysts 
